Aspirin ameliorates the long-term adverse effects of doxorubicin through suppression of cellular senescence.

ABSTRACT: A number of childhood cancer survivors develop adverse, late onset side effects of earlier cancer treatments, known as the late effects of cancer therapy. As the number of survivors continues to increase, this growing population is at increased risk for a number of health-related problems. In the present study, we have examined the effect of aspirin on the late effects of chemotherapy by treating juvenile mice with doxorubicin (DOX). This novel mouse model produced various long-term adverse effects, some of which resemble premature aging phenotypes. DOX also resulted in the tissue accumulation of senescent cells and up-regulation of cyclooxygenase-2 (COX2) expression. However, treatment with aspirin following juvenile exposure to DOX improved body weight gain, ameliorated the long-term adv

SUBMITTER: Feng M 

PROVIDER: S-EPMC6996307 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature